Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T58902
(Former ID: TTDI01298)
|
|||||
Target Name |
Tau protein aggregation (TauA)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 2 Target-related Diseases | + | ||||
1 | Acute myeloid leukaemia [ICD-11: 2A60] | |||||
2 | Alzheimer disease [ICD-11: 8A20] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | LMT-X | Drug Info | Phase 3 | Acute myeloid leukaemia | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | LMT-X | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease. Correction in: volume 31 on page 81. | |||||
REF 2 | ClinicalTrials.gov (NCT01689246) Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.